KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBT Margin (2016 - 2025)

Historic EBT Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 61.81%.

  • Halozyme Therapeutics' EBT Margin rose 48800.0% to 61.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.02%, marking a year-over-year increase of 93400.0%. This contributed to the annual value of 54.87% for FY2024, which is 128700.0% up from last year.
  • Per Halozyme Therapeutics' latest filing, its EBT Margin stood at 61.81% for Q3 2025, which was up 48800.0% from 62.92% recorded in Q2 2025.
  • Halozyme Therapeutics' EBT Margin's 5-year high stood at 67.07% during Q2 2021, with a 5-year trough of 19.7% in Q2 2022.
  • Moreover, its 5-year median value for EBT Margin was 50.89% (2024), whereas its average is 49.2%.
  • Per our database at Business Quant, Halozyme Therapeutics' EBT Margin soared by 555800bps in 2021 and then plummeted by -473700bps in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' EBT Margin stood at 53.73% in 2021, then decreased by -27bps to 39.0% in 2022, then grew by 13bps to 43.98% in 2023, then skyrocketed by 36bps to 59.8% in 2024, then increased by 3bps to 61.81% in 2025.
  • Its EBT Margin was 61.81% in Q3 2025, compared to 62.92% in Q2 2025 and 54.3% in Q1 2025.